CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

June 30, 2008

Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
DRUG

cetuximab

400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression

DRUG

gemcitabine

1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles

DRUG

gemcitabine

1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles

DRUG

cetuximab

400 mg/m2 first dose followed by 250 mg/m2 weekly

Trial Locations (25)

16100

Ospedale Villa Scassi, Genova

20052

Ospedale S. Gerado, Monza

20100

Ospedale S. Giuseppe, Milan

20132

Istituto Scientifico S. Raffaele, Milan

20142

Ospedale S. Paolo, Milan

21047

Azienda Ospedaliera Di Busto Arsizio, Saronno

23039

Ospedale E. Morelli, Sondalo

30033

Divisione di Oncologia Medica, U.S.L.L. 13, Noale

38062

Presidio Ospedaliaro Alto Gardo e Ledro, Arco

38100

Ospedale S. Chiara, Trento

46100

Azienda Ospedaliera C. Poma, Mantova

53100

Azienda Ospedaliera Universitaria Senese, Siena

59100

Ospedale di Prato, Prato

61032

Ospedale S. Croce, Fano

61100

Ospedale S. Salvatore, Pesaro

66013

Università di Chieti, Chieti

80131

Azienda Ospedaliera Cardarelli, Napoli

Second University of Naples, Napoli

83024

Azienda Sanitaria S. Giuseppe Moscati, Monteforte Irpino

84014

Ospedale Civile Umberto I, Nocera Inferiore

86100

Ospedale A. Cardarelli, Campobasso

90127

Policlinico Giaccone, Palermo

98148

Azienda Ospedaliera Universitaria Policlinico G. Martino, Messina

03031

Ospedale Umberto di Frosinone, Frosinone

04024

Ospedale di Gaeta, Gaeta

All Listed Sponsors
lead

National Cancer Institute, Naples

OTHER

NCT00330746 - CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer | Biotech Hunter | Biotech Hunter